Mostrar el registro sencillo del ítem

dc.contributor.authorGiustina, A.
dc.contributor.authorBronstein, M. D.
dc.contributor.authorChanson, P.
dc.contributor.authorPetersenn, S.
dc.contributor.authorCasanueva Freijo, Felipe 
dc.contributor.authorSert, C.
dc.contributor.authorHouchard, A.
dc.contributor.authorMelmed, S.
dc.date.accessioned2021-11-04T10:49:00Z
dc.date.available2021-11-04T10:49:00Z
dc.date.issued2019
dc.identifier.issn1386-341X
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/31338660es
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6728296/pdf/11102_2019_Article_977.pdfes
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/31338660es
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6728296/pdf/11102_2019_Article_977.pdfes
dc.identifier.urihttp://hdl.handle.net/20.500.11940/15642
dc.description.abstractPURPOSE: The SAGIT(R) instrument, designed to assist clinicians to stage acromegaly, assess treatment response and adapt patient management, was well received by endocrinologists in a pilot study. We report an interim analysis of baseline data from the validation phase. METHODS: The SAGIT(R) validation study (ClinicalTrials.gov NCT02539927) is an international, non-interventional study. Data collection included: demographic/disease characteristics; medical/surgical histories; concomitant acromegaly treatments; investigators' subjective evaluation of disease-control status (clinical global evaluation of disease control [CGE-DC]; controlled/not controlled/yet to be clarified) and clinical disease activity (active/not active); growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels; investigators' therapeutic decision. RESULTS: Of 228 patients enrolled, investigators considered disease to be controlled in 110 (48.2%), not controlled in 105 (46.1%), and yet to be clarified in 13 (5.7%) according to CGE-DC. Thirty-three patients were treatment-naive (not controlled, n = 31; yet to be clarified, n = 2). Investigators considered 48.2% patients in the controlled and 95.2% in the not-controlled groups to have clinically active disease. In the controlled group, 29.7% of patients did not exhibit hormonal control (GH </= 2.5 microg/L; normalized IGF-1) and 47.3% did not have rigorous hormonal control (GH < 1.0 microg/L; normalized IGF-1) by contemporary consensus. Current acromegaly treatment was continued with no change for 91.8% of patients in the controlled and 40.0% in the not-controlled groups. CONCLUSIONS: These data highlight discrepancies between investigator-evaluated disease-control status, disease activity, hormonal control, and treatment decisions in acromegaly. Once validated, the SAGIT(R) instrument may assist clinicians in making active management decisions for patients with acromegaly.en
dc.language.isoenges
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshAdult*
dc.subject.meshMiddle Aged*
dc.subject.meshInsulin-Like Growth Factor I*
dc.subject.meshHumans*
dc.subject.meshPilot Projects*
dc.subject.meshHuman Growth Hormone*
dc.subject.meshAged*
dc.subject.meshAcromegaly*
dc.titleStaging and managing patients with acromegaly in clinical practice: baseline data from the SAGIT (R) validation studyes
dc.typeArtigoes
dc.identifier.doi10.1007/s11102-019-00977-5
dc.identifier.pmid31338660
dc.identifier.sophos31239
dc.issue.number5es
dc.journal.titlePituitaryes
dc.organizationServizo Galego de Saúdees
dc.page.initial476es
dc.page.final487es
dc.rights.accessRightsopenAccesses
dc.subject.decsfactor I de crecimiento insulinoide*
dc.subject.decsanciano*
dc.subject.decsproyectos piloto*
dc.subject.decsmediana edad*
dc.subject.decshumanos*
dc.subject.decsacromegalia*
dc.subject.decsadulto*
dc.subject.decshormona del crecimiento humana*
dc.subject.keywordCHUSes
dc.typefidesArtículo Originales
dc.typesophosArtículo Originales
dc.volume.number22es


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional